Loading…
Bioventus Inc. is projected to rise to $11.24 by 2027, a +26% move from its current price of $8.90. BVS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $8.65 | $8.90 | $9.15 | +0.01% |
| May 30 | $8.55 | $8.90 | $9.26 | +0.02% |
| May 31 | $8.48 | $8.90 | $9.35 | +0.03% |
| Jun 1 | $8.42 | $8.90 | $9.42 | +0.04% |
| Jun 2 | $8.36 | $8.90 | $9.48 | +0.05% |
| Jun 3 | $8.31 | $8.90 | $9.54 | +0.05% |
| Jun 4 | $8.27 | $8.91 | $9.59 | +0.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.27 | $8.91 | $9.59 | +0.06% |
| Week 2 | $8.02 | $8.91 | $9.90 | +0.13% |
| Week 3 | $7.84 | $8.92 | $10.14 | +0.19% |
| Week 4 | $7.69 | $8.92 | $10.36 | +0.25% |
| Week 5 | $7.56 | $8.93 | $10.55 | +0.32% |
| Week 6 | $7.44 | $8.93 | $10.72 | +0.38% |
| Week 7 | $7.34 | $8.94 | $10.89 | +0.44% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bioventus Inc. is a medical device company focused on relieving pain and addressing musculoskeletal therapies in the United States and internationally. Its product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products.
Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc.
was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus Inc. (BVS) is a healthcare company operating in the medical device space. The current price is $9.28 per share, and the market capitalization is $628.7M, with a rank of 2866.
The stock trades in the context of a broader forecast that envisions a bullish multi-year path beyond 2026. The 2026 forecast shows a min of $7.21, an avg of $9.28, and a max of $14.11, with neutral sentiment and 0% ROI. From 2027 onward, the outlook turns bullish with higher average prices and meaningful ROI gains through 2050.
By 2030 the average is $16.68, by 2040 $53.19, and by 2050 $106.51, reflecting a sustained long-term upside.
A major floor 15.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 22.9% above — a clean break opens room to run.
A major ceiling 30.6% above — clearing it would confirm fresh momentum.
Key BVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.53 | Sell | $9.40 | Sell |
| MA 10 | $10.05 | Sell | $9.77 | Sell |
| MA 20 | $10.17 | Sell | $9.95 | Sell |
| MA 50 | $9.72 | Sell | $9.70 | Sell |
| MA 100 | $8.99 | Sell | $9.14 | Sell |
| MA 200 | $8.08 | Buy | $8.58 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.83 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -173.54 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.23 | Sell |
| ROC (12) | -15.24 | Sell |
| Bollinger %B (20,2) | -0.03 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.21 | Buy |
| Awesome (5,34) | -0.53 | Sell |
| Ultimate (7,14,28) | 20.60 | Buy |
| Momentum (10) | -1.24 | Sell |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 8.76 | Buy |
| ADX (14) | 20.96 | Sell |
| ATR (14) | 0.26 | Info |
The near-term technical picture shows bullish sentiment in the background, with RSI(14) at 40. The stock trades above the 200-day and near the 50-day moving average, with the SMA50 at $9.71 and the SMA200 at $8.06. A key support level sits at $9.28 and a resistance level at $10.94.
The current 30-day price range runs from $7.66 to $11.25, illustrating a relatively wide but constructive trading band as investors size up the name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.21 | $8.90 | $13.25 | 0% | Neutral | |
| $8.89 | $11.24 | $15.08 | +26% | Bullish | |
| $9.51 | $12.37 | $17.22 | +39% | Bullish | |
| $10.27 | $13.67 | $19.58 | +54% | Bullish | |
| $11.11 | $15.11 | $22.18 | +70% | Bullish | |
| $12.53 | $17.37 | $26.04 | +95% | Bullish | |
| $14.79 | $20.87 | $31.90 | +135% | Bullish | |
| $17.57 | $25.21 | $39.22 | +183% | Bullish | |
| $18.36 | $26.77 | $42.31 | +201% | Bullish | |
| $18.30 | $27.09 | $43.46 | +204% | Bullish | |
| $27.88 | $44.24 | $75.58 | +397% | Bullish | |
| $48.35 | $86.54 | $161.95 | +872% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $7.21 | $8.90 | $10.50 | +0.00% |
| June 2026 | $7.72 | $9.07 | $10.91 | +1.88% |
| July 2026 | $7.57 | $8.97 | $10.95 | -1.03% |
| August 2026 | $7.75 | $9.26 | $11.42 | +3.14% |
| September 2026 | $8.14 | $9.77 | $12.16 | +5.59% |
| October 2026 | $8.24 | $9.95 | $12.47 | +1.77% |
| November 2026 | $8.26 | $10.02 | $12.65 | +0.71% |
| December 2026 | $8.57 | $10.43 | $13.25 | +4.11% |
Click any year to see its month-by-month BVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BVS could reach as high as $13.25, with a base case around $8.90 and support toward $7.21 — roughly 0% from $8.90. Price action looks broadly range-bound.
Expect BVS to range from $8.89 to $15.08 through 2027. The $11.24 average target implies a +26% move from current prices. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The BVS price prediction for 2028 points to an average of $12.37 (low $9.51, high $17.22) — a potential gain of +39% on today's $8.90. Momentum favours further upside here.
In 2029, BVS is projected to trade between $10.27 and $19.58, averaging $13.67 — a potential gain of +54% from today's $8.90. That is up +10% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Bioventus Inc.'s 2030 outlook centres on $15.11, within a $11.11 to $22.18 range. That is up +11% on the projected 2029 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2031, BVS could reach as high as $26.04, with a base case around $17.37 and support toward $12.53 — roughly +95% from $8.90. Buyers look set to stay in control over this stretch.
Expect BVS to range from $14.79 to $31.90 through 2032. The $20.87 average target implies a +135% move from current prices. That is up +20% on the projected 2031 average. Momentum favours further upside here.
The BVS price prediction for 2033 points to an average of $25.21 (low $17.57, high $39.22) — a potential gain of +183% on today's $8.90. Buyers look set to stay in control over this stretch.
In 2034, BVS is projected to trade between $18.36 and $42.31, averaging $26.77 — a potential gain of +201% from today's $8.90. That is up +6% on the projected 2033 average. Momentum favours further upside here.
Bioventus Inc.'s 2035 outlook centres on $27.09, within a $18.30 to $43.46 range. That is up +1% on the projected 2034 average. That marks a +204% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BVS could reach as high as $75.58, with a base case around $44.24 and support toward $27.88 — roughly +397% from $8.90. Momentum favours further upside here.
Expect BVS to range from $48.35 to $161.95 through 2050. The $86.54 average target implies a +872% move from current prices. That is up +96% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BVS today (≈ 112.359551 BVS) could be worth
$9,723.17
+$8,723.17 (+872%) by 2050 · US Dollar
Based on the average projected BVS price of $86.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BVSwould be worth at today's price.
$1,000 invested in BVS on May 27, 2025 (≈ 153.139352 BVS) would be worth
$1,362.94
+$362.94 (+36.3%) today · 1.36× · US Dollar
Based on a BVS entry price of $6.53 vs. today's $8.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $10.94 | $813.53 | -18.6% |
| 1 month ago | $10.01 | $889.11 | -11.1% |
| 3 months ago | $8.86 | $1,004.51 | +0.5% |
| 6 months ago | $7.59 | $1,172.6 | +17.3% |
| 1 year ago | $6.53 | $1,362.94 | +36.3% |
| All time (5.0y) ago | $17.9 | $497.21 | -50.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BVS forecast.
Our base-case forecast reaches $18.00 around 2032.
Implied market cap at $18.00: $1.22B
The multi-year forecast depicts a clear bullish trajectory after 2026, with rising average prices and growing ROI. In 2026 the average is $9.28 with a neutral sentiment and 0% ROI. By 2027 the average climbs to $11.92 and the max to $16.08, with a 28.5% ROI and bullish sentiment, followed by 2028 at an average of $13.37 and a 44% ROI.
The path continues higher through 2029 (avg $15.10, ROI 62.7) and 2030 (avg $16.68, ROI 79.8), underscoring a sustained bullish tone. Beyond 2030, the forecast shows continued upside, with 2040 averaging $53.19 and a 473.1% ROI, and 2050 averaging $106.51 with a 1047.7% ROI. These numbers illustrate a long-run bullish framework but remain estimates, not guarantees, and actual results can vary.
Risks include volatility within the forecast ranges, as the max values rise alongside the average in later years (e.g., 2032 max $37.18, 2033 max $45.45, 2034 max $49.45, and 2035 max $51.15), highlighting that outcomes are uncertain and contingent on future conditions.
Tap a question to reveal the answer.
Average forecast price: $16.68; min $12.18; max $24.68; ROI 79.8%; sentiment BULLISH.
Yes. The 2035 forecast lists a max of $51.15, with an average of $31.55 and a min of $21.09; sentiment BULLISH.
The outlook turns bullish from 2027 onward, with rising averages and ROI, including 2040 ROI 473.1% and 2050 ROI 1047.7%.
Current price is $9.28; Market cap is $628.7M.
Average forecast price: $53.19; min $33.05; max $91.92; ROI 473.1%; sentiment BULLISH.
Bioventus Inc. Community Discussion
0Share your Bioventus Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.